238 related items for PubMed ID: 35762436
1. [Association of liver damage with coronary artery lesion and no response to intravenous immunoglobulin in the acute stage of Kawasaki disease].
Hu HM, Chen XZ, Zhang YL, DU ZD.
Zhongguo Dang Dai Er Ke Za Zhi; 2022 Jun 15; 24(6):681-686. PubMed ID: 35762436
[Abstract] [Full Text] [Related]
2. Evaluation of laboratory predictors for intravenous immunoglobulin resistance and coronary artery aneurysm in Kawasaki Disease before and after therapy.
Liu J, Ye B, Su D, Qin S, Zhao W, Pang Y.
Clin Rheumatol; 2023 Jan 15; 42(1):167-177. PubMed ID: 36129563
[Abstract] [Full Text] [Related]
3. Predictors for Intravenous Immunoglobulin Resistance in Patients with Kawasaki Disease.
Li W, Zhang L, Wang Z, He X, Lin H, Wang Y, Yuan J, Xie X, Zhang X, Qin Y, Huang P.
Int J Clin Pract; 2022 Jan 15; 2022():2726686. PubMed ID: 35989868
[Abstract] [Full Text] [Related]
4. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH.
PLoS One; 2015 Jan 15; 10(12):e0144603. PubMed ID: 26658843
[Abstract] [Full Text] [Related]
5. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR.
Pediatr Infect Dis J; 2018 Oct 15; 37(10):976-980. PubMed ID: 29461447
[Abstract] [Full Text] [Related]
6. Serum amyloid A as a biomarker for immunoglobulin resistance in Kawasaki disease.
Huang XB, Zhao S, Liu ZY, Xu YY, Deng F.
Ann Med; 2023 Oct 15; 55(2):2264315. PubMed ID: 37870383
[Abstract] [Full Text] [Related]
7. [Expression of interleukin-17A in serum of children with intravenous immunoglobulin-resistant Kawasaki disease and its clinical significance].
Li SY, Ding Y.
Zhongguo Dang Dai Er Ke Za Zhi; 2023 Mar 15; 25(3):244-249. PubMed ID: 36946157
[Abstract] [Full Text] [Related]
8. Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm.
Wu Y, Liu FF, Xu Y, Wang JJ, Samadli S, Wu YF, Liu HH, Chen WX, Luo HH, Zhang DD, Wei W, Hu P.
Clin Exp Med; 2019 May 15; 19(2):173-181. PubMed ID: 30617865
[Abstract] [Full Text] [Related]
9. [Association between duration of fever before treatment and intravenous immunoglobulin resistance in Kawasaki disease].
Wang X, Pan SL, DU ZH, Ji ZX, Luo G, Sun HX, Ma SJ.
Zhongguo Dang Dai Er Ke Za Zhi; 2022 Apr 15; 24(4):399-404. PubMed ID: 35527415
[Abstract] [Full Text] [Related]
10. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
Yılmazer MM, Özdemir R, Meşe T, Küçük M, Öner T, Devrim İ, Bayram N, Güven B, Tavlı V.
Turk J Pediatr; 2019 Apr 15; 61(5):648-656. PubMed ID: 32104995
[Abstract] [Full Text] [Related]
11. [Predictive indicators and risk model construction for coronary artery lesions in Kawasaki disease children over 5 years old].
Zhang H, Zhang Y.
Zhongguo Dang Dai Er Ke Za Zhi; 2024 May 15; 26(5):461-468. PubMed ID: 38802905
[Abstract] [Full Text] [Related]
12. [A retrospective analysis of 602 Kawasaki disease cases with electronic data capture system].
Xie L, Zhou C, Wang R, Xiao T, Shen J, Huang M.
Zhonghua Er Ke Za Zhi; 2015 Jan 15; 53(1):34-9. PubMed ID: 25748402
[Abstract] [Full Text] [Related]
13. Risk factors for coronary artery lesions in children with Kawasaki disease.
Duan J, Jiang H, Lu M.
Arch Argent Pediatr; 2020 Oct 15; 118(5):327-331. PubMed ID: 32924395
[Abstract] [Full Text] [Related]
14. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM, Silverman ED, McCrindle BW, Yeung RS.
J Pediatr; 2002 Apr 15; 140(4):450-5. PubMed ID: 12006960
[Abstract] [Full Text] [Related]
15. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
Qin LJ, Wang HW, Hu XF, Liu QJ, Shi H, Wei YX, Chen QJ, Cheng PX.
Zhonghua Er Ke Za Zhi; 2006 Dec 15; 44(12):891-5. PubMed ID: 17254453
[Abstract] [Full Text] [Related]
16. Prediction of repeated intravenous immunoglobulin resistance in children with Kawasaki disease.
Lu Y, Chen T, Wen Y, Si F, Wu X, Yang Y.
BMC Pediatr; 2021 Sep 16; 21(1):406. PubMed ID: 34530763
[Abstract] [Full Text] [Related]
17. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H.
Postgrad Med; 2018 May 16; 130(4):442-447. PubMed ID: 29745742
[Abstract] [Full Text] [Related]
18. Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.
Xie T, Wang Y, Fu S, Wang W, Xie C, Zhang Y, Gong F.
Pediatr Rheumatol Online J; 2017 Mar 21; 15(1):17. PubMed ID: 28320400
[Abstract] [Full Text] [Related]
19. Clinical features of recurrent Kawasaki disease and its risk factors.
Yang HM, Du ZD, Fu PP.
Eur J Pediatr; 2013 Dec 21; 172(12):1641-7. PubMed ID: 23887608
[Abstract] [Full Text] [Related]
20. A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?
Li W, He X, Zhang L, Wang Z, Wang Y, Lin H, Yuan J, Xie X, Qin Y, Huang P.
Cardiovasc Ther; 2021 Dec 21; 2021():6660407. PubMed ID: 34239607
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
